Cooperative Agreement UH2CA290587
Award Date
4/3/25
Completion Date
3/31/26
Dollars Obligated
$310K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10016, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is supporting the development and application of a new epigenome sequencing platform called Glycosylase-Implemented Epigenome Sequencing (GLIMP-SEQ). The $230,010 award to the University of Chicago aims to create a highly sensitive and accurate method for profiling 5-methylcytosine (5mC) modifications in degraded clinical samples such as formalin-fixed, paraffin-embedded (FFPE)...
The National Cancer Institute (NCI) has awarded a $647,458 Cooperative Agreement to the Massachusetts Institute of Technology (MIT) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The project aims to develop a novel platform that enables real-time functional assessment of acute myeloid leukemia (AML) measurable residual disease (MRD) therapeutic vulnerabilities.
The key products and services to be delivered under this award include: 1) Discovering and analyzing...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) is for the development and optimization of a scalable single-cell multi-omic profiling method called SHARE-ME-SEQ. This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of making a substantive leap in acute myeloid leukemia (AML) treatment by identifying and targeting methylation-driven pathways.
The...
This $416,745 Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The key products and services to be delivered under this 3-year project include:
Creation of a Regulatory-Element-Target-Gene Atlas to enable researchers to explore connections between regulatory elements and cancer-associated...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a highly sensitive DNA hypermethylation-based kit to identify Barrett's Esophagus patients at high risk of progressing to esophageal adenocarcinoma. The $398,738 award to Pre-Cancer Diagnosis, LLC will validate the use of DNA methylation markers to predict high-risk Barrett's Esophagus progression and develop a targeted methylation panel for a diagnostic...
This Cooperative Agreement award of $356,850 from the National Cancer Institute (NCI), under the Cancer Treatment Research grant program (CFDA 93.395), aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes in liquid biopsy-based cancer research and clinical testing.
The project, led by Oregon Health & Science University (OHSU), focuses on characterizing the pre-analytical steps involved in blood and bone marrow...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is focused on the development and clinical validation of Precision Epigenomics Inc.'s Sentinel-MPE liquid biopsy assay. The Sentinel-MPE test is a multi-cancer detection product aimed at improving the diagnosis of malignant pleural effusions, which can be challenging to distinguish from benign effusions using conventional cytology methods. The $2,078,214 award supports a...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...
This $396,161 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel aqueous humor-based multiplex assay for predicting the metastatic risk of uveal melanoma. The project, awarded to Olmeda Biosciences LLC, seeks to create an easy-to-use, minimally invasive pre-clinical test that utilizes protein biomarkers from the aqueous humor (the clear fluid in the front chamber of the eye) to improve the accuracy of...
This $370,575 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) is funding research by The University of Texas MD Anderson Cancer Center to develop DNA methylation-based biomarkers for prognosis and treatment selection in adenoid cystic carcinoma (ACC), a common salivary gland cancer.
The key objectives are to: 1) Examine DNA methylation and transcriptomic profiles in 200 clinically annotated ACC tumors to...